FB102
✓ Phase 2 complete
argenx (ex-Forte)
Anti-CD122 antibody
Phase 2 in 126 adults protected the gut lining during gluten exposure. Moving to phase 3.
Next: phase 3
Autoimmune · small intestine
Celiac Disease
Gluten makes the immune system attack the gut. No drug has been approved; the leading candidates aim to protect the gut from accidental exposure.
- Cure
- None yet
- Current treatment
- Lifelong gluten-free diet
- Who has it
- About 1 in 100 people
- Updated
9candidates on the board
Phase 2 completefurthest phase
3updates in 2026
What changed
The latest developments, newest first.
ProgressFB102 clears phase 2, heads to phase 3
In 126 adults exposed to gluten, it protected the villi better than placebo. Analysts project a launch around 2031.
ProgressTEV-53408 prevents gut damage
One dose protected the gut through six weeks of daily gluten. Teva plans a dose-finding study.
StoppedTakeda drops TAK-101
Having dropped zamaglutenase in 2025, Takeda is left with only TAK-227.
Treatments in development
Each column is a step on the road to the pharmacy. Colors show the type of treatment.
- Antibody or biologic (5)
- Oral drug (2)
- Vaccine, device or other (2)
Phase 2efficacy and dose · 7
TEV-53408
Teva
Anti-IL-15 antibody
Phase 2a in 50 adults: prevented gut damage over 6 weeks of daily gluten.
Result: Sep 2026
Latiglutenase
✓ Phase 2 complete
Entero Therapeutics
Gluten-digesting enzyme
Taken with meals. The company says it is ready for phase 3, no date yet.
Awaiting phase 3
KAN-101
Anokion · Pfizer Ignite
Immune tolerance (nanoparticle)
Aims to teach the body to tolerate gluten. Fewer symptoms at every dose in phase 2.
Result: Jan 2025
TAK-227
Takeda · Zedira
Transglutaminase 2 inhibitor
Blocks the enzyme that makes gluten visible to the immune system.
In phase 2
Amlitelimab
Sanofi
Anti-OX40L antibody
For people still symptomatic on the diet. Enrollment complete.
Data: 2027
DONQ52
Chugai (Roche)
Gluten + HLA-DQ2.5 antibody
For gut damage despite a strict diet.
Recruiting
Phase 1safety · 2
ANB033
First Tracks Bio
CD122 antagonist
Tests damage prevention and gut healing.
Data: Q4 2026
VTP-1000
Barinthus Bio
Immune tolerance (nanoparticle)
Injection of gluten peptides plus rapamycin. No serious effects in stage one.
Data: H2 2026
Left behind
Candidates that looked promising and were stopped. Most treatments tested never reach the market.
TAK-101
2026 · Tolerance nanoparticle (Takeda), after phase 2.
Zamaglutenase
2025 · Gluten-digesting enzyme (Takeda), in phase 2.
Larazotide
2022 · Phase 3 showed no benefit.
Nexvax2
2019 · Therapeutic vaccine; did not beat placebo.
Frequently asked questions
Is there a cure for Celiac Disease?
None yet. Current treatment: Lifelong gluten-free diet.
Which Celiac Disease treatments are being tested?
Fasevia tracks 9 candidates: FB102 (Phase 2 complete); Latiglutenase (Phase 2 complete); TEV-53408 (Phase 2); KAN-101 (Phase 2); TAK-227 (Phase 2); Amlitelimab (Phase 2); DONQ52 (Phase 2); ANB033 (Phase 1); VTP-1000 (Phase 1).
What is the most advanced Celiac Disease treatment in development?
The furthest along today is FB102 (argenx (ex-Forte)), in phase 2 complete. Phase 2 in 126 adults protected the gut lining during gluten exposure. Moving to phase 3.
When could a new Celiac Disease treatment arrive?
A drug has to complete phase 3 and be reviewed by health agencies such as the FDA or EMA, which usually takes several years. The leading candidate today is in phase 2 complete.